Heartbeam Inc's Comment on Sales, Marketing and Customers
The company serves concierge physicians, preventative cardiology practices, cardiology departments of hospitals, and healthcare insurers. Its initial target market segments for the HeartBeam System include concierge practices, the hospital-at-home segment, and clinical trials, focusing on users seeking a medical-grade ECG device outside established reimbursement systems. The company engages with concierge practices and hospitals within large healthcare systems through clinical data, technical presentations, and demonstration projects to facilitate market penetration. Its strategy involves partnering with health insurance companies to obtain coverage based on demonstrated clinical efficacy and cost-effectiveness. The company plans to establish a direct sales network experienced in these target markets and to continue clinical trials with leading cardiologists to build evidence and reference sites. The HeartBeam System is supported by clinical data from the VALID-ECG pivotal study, which validated its performance for arrhythmia detection and was presented at the Heart Rhythm Society conference in April 2025.
Heartbeam Inc’s Comment on Sales, Marketing and Customers
The company serves concierge physicians, preventative cardiology practices, cardiology departments of hospitals, and healthcare insurers. Its initial target market segments for the HeartBeam System include concierge practices, the hospital-at-home segment, and clinical trials, focusing on users seeking a medical-grade ECG device outside established reimbursement systems. The company engages with concierge practices and hospitals within large healthcare systems through clinical data, technical presentations, and demonstration projects to facilitate market penetration. Its strategy involves partnering with health insurance companies to obtain coverage based on demonstrated clinical efficacy and cost-effectiveness. The company plans to establish a direct sales network experienced in these target markets and to continue clinical trials with leading cardiologists to build evidence and reference sites. The HeartBeam System is supported by clinical data from the VALID-ECG pivotal study, which validated its performance for arrhythmia detection and was presented at the Heart Rhythm Society conference in April 2025.
Sources:
Heartbeam Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Heartbeam Inc’s corporate clients.
For your research, we’ve provided 9 tables on Heartbeam Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
